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Conclusion: Most of the modulation indexes proposed in the 
literature are related to the robustness and modulation of a 
plan. However, none of them has been conceived to 
appropriately predict the interplay effect in lung SABR. MIt 
has been found to be the only published index capable of 
detecting failing plans. MIt and PUMA have the same 
specificity since both detected all of the failing plans. 
However, PUMA has a greater accuracy and sensitivity. 
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Purpose or Objective: The objective of this HERO study was 
to assess the number of new cancer patients that will require 
at least one course of radiotherapy by 2025 compared to the 
2012 figure, by tumor site and European country. 
 
Material and Methods: European cancer incidence data by 
tumor site and country for 2012 and 2025 was extracted from 
the GLOBOCAN database. The projection of the number of 
new cases took into account demographic factors (age and 
size of the population). Population based stages at diagnosis 
were taken from four European countries. Incidence and 
stage data were introduced in the Australian Collaboration 
for Cancer Outcomes Research and Evaluation (CCORE) 
model,  thus producing an evidence-based proportion of 
incident cases with an indication for radiotherapy, the 
Optimal Utilization Proportion (OUP).  From these values, the 
number of cases that would require radiotherapy on an 
annual basis in each country was calculated. 
 
Results: Among the difference tumor sites, the highest 
expected relative increase by 2025 in treatment courses was 
prostate cancer (24%) while lymphoma (13%), head and neck 
(12%) and breast cancer (10%) were below the average. 
Cervical (1%) and testicular cancer (-6%) were the sites with 
the lowest expected increase. Based on the projected cancer 
distributions in 2025, a 16% expected increase in the number 
of radiotherapy treatment courses was estimated. This 
increase varied across European countries from less than 5% 
(Bulgaria, Latvia, Lithuania, Ukraine, Belarus, Estonia, 
Moldova) to more than 30% (Switzerland, Luxembourg, Malta, 
Iceland, Ireland, Albania, Cyprus). 
 
Conclusion: This HERO study showed that the need for 
radiotherapy in Europe is, on average, expected to increase 
with 16% over the next decade. The expected changes varied 
considerably between countries (range 0-38%). With the 
already existing disparity in radiotherapy resources in mind, 
the data provided here should act as a leverage point to raise 
awareness among European health policy makers of the need 
for investment in radiotherapy.  
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Purpose or Objective: Current clinical trials and studies are 
identifying hypofractionation as a viable treatment option 
when compared with current fractionation regimens. Our 
work estimates the reduction in the number of fractions 
prescribed and the potential effect on the overall demand for 
radiotherapy across the whole of England. With the evidence 
based estimates of demand for radiotherapy currently 
outstripping the supply capacity in England, this potential 
reduction in fraction demand needs to be calculated to assess 
the potential effects for radiotherapy service and 
infrastructure planning. 
 
Material and Methods: The Malthus Program, a tool for 
modelling radiotherapy demand, was used to calculate the 
potential effect of three hypofractionation studies/trials for 
the population of England. Well-published and potential 
clinical indications for hypofractionation have been modelled 
for prostate cancer, non-small cell lung cancer (NSCLC) and 
breast cancer. The hypofractionation indications for 
radiotherapy were mapped into the original Malthus clinical 
decision trees and simulations completed to study the effects 
of hypofractionation on demand. 
 
Results: If the CHHiP prostate trial achieves universal uptake 
throughout England then it has the potential to reduced 
radiotherapy demand by 3,500 fractions per million 
population (#pmp). SBRT for medically inoperable (or refusal 
of surgery) for stage 1 and stage 2 NSCLC has the potential to 
reduce the demand by a further 700 #pmp. The FAST-Forward 
trial, using 5# instead of 15# for T1-3 N0-1 M0 breast cancer 
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has the potential to reduce demand by 4,600 #pmp. A 
potential reduction in modelled demand of 8,800 #pmp arises 
from these three studies alone. Across the total population of 
England, this translates to approximately 479,600 fractions 
per year. 
 
Conclusion: The current clinical indications and trials for 
hypofractionation have the potential to reduce the evidence-
based estimates of demand of radiotherapy sufficiently to be 
achievable with a modest increase of the current levels of 
equipment in England. While the presented calculations are 
for England as a whole, the Malthus program offers the 
facility to calculate the changes in modelled demand at a 
regional level within England, enabling a more precise 
calculation for treatment centres and their local catchment. 
 
SP-0333  
Evaluation of radiotherapy utilisation in Belgium: patterns 
and possible causes of suboptimal use 
E. Van Eycken
1Belgian Cancer Registry, Brussels, Belgium 
1, H. De Schutter1, K. Stellamans2, M. 
Rosskamp1, Y. Lievens3 
2General Hospital Groeninge, Radiation Oncology, Kortrijk, 
Belgium 
3Ghent University Hospital, Radiation Oncology, Ghent, 
Belgium 
 
Using the evidence-based decision analytic model developed 
by the Collaboration for Cancer Outcomes, Research and 
Evaluation (CCORE) (1), the ESTRO-HERO project (2,3) 
calculated that 53.2% of incident cancer patients in Belgium 
would require external beam radiotherapy during the course 
of their disease. In order to find out what is the actual 
utilization of radiotherapy in Belgium and how it compares 
with this calculated optimal utilization proportion (OUP), a 
population consisting of 112,235 patients with a unique 
invasive cancer diagnosis in the years 2009 and 2010 was 
evaluated. Tumour categories were defined according to the 
CCORE methodology. For each cancer, the data set consisted 
of the incidence date, topography, histology, TNM stage and 
the treatment recommendations formulated during the 
multidisciplinary team meetings (MDT), the latter giving an 
indication on the pattern of radiotherapy prescription in 
Belgium. Data on reimbursement for external beam 
radiotherapy, obtained through linkage with the 
administrative database from the Health Insurance 
Companies and covering a time period up till 3 years after 
the year of incidence, provided insight in the actual 
utilization. Besides overall analyses at the Belgian population 
level, variability of actual and optimal utilization amongst 
cancer types was assessed. 
For the Belgian cancer population diagnosed in 2009-2010, 
the actual use of radiotherapy was 35.1%. About 3 in 4 of 
these patients received radiotherapy within the first 9 
months after diagnosis, providing an estimate of those 
irradiated in the context of the primary treatment strategy. 
The global result was in line with the percentage of 
prescribed or recommended radiotherapy series (35.0%) 
during the MDT.  
Radiotherapy uptake varied with primary tumour site. Most of 
the cancers in Belgium have a lower actual utilization than 
predicted with the exception of leukaemia, ovarian, thyroid, 
testicular, colon and liver cancer. Most pronounced 
differences between optimal and actual utilization were 
found in less typical radiotherapy indications such as in 
bladder, brain, lymphoma, myeloma, pancreas and stomach 
cancer. For more common radiotherapy indications such as 
breast, head and neck and rectal cancer, the underutilization 
is about 10-15% while in lung, oesophagus and prostate 
cancer, the underuse was more pronounced resulting in only 
about 55-60% of the patients requiring radiotherapy being 
actually treated.  
These data, derived at the unique patient-level, illustrate 
that even in a country that is well-resourced in terms of 
radiotherapy staffing and infrastructure, a clear discrepancy 
can be observed between the optimal and actual 
radiotherapy delivery. Potential reasons for this may include 
physician and patient preferences favouring non-radiotherapy 
regimens in case of competing treatment modalities (e.g. in 
prostate cancer), deviation from guidelines (e.g. due to 
comorbidity or low performance status), an overestimation of 
the real needs by the evidence-based OUP-model and an 
underestimation of the actual utilisation due to available 
nomenclature data being limited to 3 years after incidence. 
These reasons all deserve further evaluation and they must 
be carefully taken into account when forecasting and 
planning radiotherapy staffing and infrastructure.  
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European countries have a several decade long history of 
planning for cancer services and cancer care. The World 
Health Organization (WHO), whose focus was on middle-
income countries, had launched the original initiative. WHO 
at that time at the beginning of the 1980s also proposed the 
first comprehensive definition of National Cancer Control 
Programmes (NCCP): “A national cancer control programme 
is a public health programme designed to reduce the number 
of cancer cases and deaths and improve quality of life of 
cancer patients, through the systematic and equitable 
implementation of evidence-based strategies for prevention, 
early detection, diagnosis, treatment, and palliation, making 
the best use of available resources.” Cancer control 
programmes bear different names – cancer plans, cancer 
control programmes, cancer strategies, etc. They may be 
national or regional, but in either case they are closely 
related with the decision-making authorities. They depend on 
the appropriate allocation of resources and on the legal 
enactment of regulation of cancer care delivery and all of its 
services and activities. The rapid growth in cancer incidence 
coupled with exorbitantly rising costs brought the reflection 
on the planning of cancer care and its services to the 
European Union’s table. As a result of the conclusions of the 
Slovenia’s Presidency to the Council of the European Union, 
an initiative called European Partnership for Action Against 
Cancer (EPAAC) was born and launched by Commissioner Dalli 
in September 2009. At the same time the European 
Commission called upon Member States (MS) to develop and 
adopt national cancer plans (NCPs) or strategies by 2013. In 
the Joint Action (JA) EPAAC, which acted as the practical 
implementation of the partnership, the status of the national 
cancer plan development was revised through a 
comprehensive survey in all MSs, Norway and Iceland. What 
should be practical consequences of an NCP? In principle they 
should be the following: Mapping all the processes belonging 
to the comprehensive control and management of 
cancerIdentifying priorities in cancer careDefining clear 
patient pathways and assuring the necessary resources for 
themSecuring sufficient financial resources through the 
implementation of both guidelines and patient 
pathwaysIntroducing new programmes – therapeutic and 
screening, treatment approaches and new concepts, such as 
survivorship.Raising awareness of the different elements in 
